Answers are grounded in this paper and cite their sources.
This reply uncovers issues in using effect sizes as non-inferiority margins in active treatments, suggesting a more cautious approach.
From 19 meta-analyses comparing active bona fide treatments, Flückiger et al. (2026) recently calculated a between-group effect size (SMD) of -0.17 for primary outcomes and of -0.16 for secondary outcomes. They suggested using these effect sizes as empirically derived non-inferiority margins. However, Flückiger et al.'s approach is conceptually problematic and lacks empirical support. Without a rationale, empirically found differences between active treatments cannot per se be regarded as non-inferiority margins.
No takes yet. Share an insight, caveat, or question.
Leichsenring et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: